Skip to main content
ZYUS Life Sciences Corporation logo

ZYUS Life Sciences Corporation — Investor Relations & Filings

Ticker · ZYUS ISIN · CA9899601095 TSXV Professional, scientific and technical activities
Open in API
Filings indexed 299 across all filing types
Latest filing 2026-05-22 Regulatory Filings
Country CA Canada
Listing TSXV ZYUS

About ZYUS Life Sciences Corporation

https://www.zyus.com/

ZYUS Life Sciences Corporation is a clinical-stage life sciences company dedicated to the development and commercialization of novel, non-opioid pharmaceutical drug candidates. The company focuses on proprietary cannabinoid-based therapeutics, or phyto-therapeutics, targeting the treatment of chronic and neuropathic pain. ZYUS's vision is to redefine the standard of care in pain management by developing evidence-based alternatives to conventional treatments, including opioids and NSAIDs. The core business involves advancing these drug product candidates through clinical trials, exemplified by the ongoing Phase 2a UTOPIA-1 trial evaluating a novel non-opioid pain drug.

Recent filings

Filing Released Lang Actions
Notice of the meeting and record date - English.pdf
Regulatory Filings Classification · 85% confidence The document is a brief compliance notification from TSX Trust confirming that the Notice of Record and Meeting Dates for the upcoming Annual General Meeting was sent to the Canadian Depository. It does not contain actual financial statements or proxy materials, nor does it announce vote results. It is a routine regulatory announcement rather than the AGM materials themselves. This fits the catch-all Regulatory Filings category (RNS).
2026-05-22 English
News release - English.pdf
Capital/Financing Update Classification · 89% confidence The document is a press release announcing the closing of a secured loan financing (first tranche of a CAD$2M secured loan) and providing an update on the company’s annual filings. This is clearly an update on the company’s financing activity rather than an AGM, financial report, audit, management change, or other category. Therefore, it should be classified as a Capital/Financing Update.
2026-05-21 English
Material change report - English.pdf
Regulatory Filings Classification · 86% confidence The document is a Canadian Form 51-102F3 Material Change Report filed under National Instrument 51-102. It discloses the issuance of a failure-to-file cease trade order and includes a news release as Schedule A. This is a regulatory compliance filing rather than an annual or interim financial report, earnings release, or management discussion. It does not fit any specific category like earnings releases or M&A, so it falls under the general Regulatory Filings (RNS) category.
2026-05-15 English
News release - English.pdf
Regulatory Filings
2026-05-07 English
News release - English.pdf
Regulatory Filings
2026-05-06 English
News release - English.pdf
Regulatory Filings
2026-05-01 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.